Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150005/S090

Intellagen Irrigation Tubing Set

Boston Scientific Corp · Decision date Dec 5, 2025

FDA DECISIONP150005/S090

What did the FDA approve?

FDA records P150005/S090 as a supplement to PMA P150005, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Dec 5, 2025.

FDA approval order statement

Approval for a new sterile pouch with direct label print and new tubing ink for the INTELLAGEN Tubing Set
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Cardiovascular
Decision date
Dec 5, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P150005/S090
Regulatory pathway
PMA supplement
Product code
OAD
Decision code
APPR
Decision date
Dec 5, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: catheter, percutaneous, cardiac ablation, for treatment of atrial flutter.

Product code
OAD
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P150005/S089 · Related supplement

    Blazer Open-Irrigated Ablation Catheter

  2. P150005/S088 · Related supplement

    Opal HDx Ablation Connection Box (Maestro); Opal HDx Ablation Connection Box - IntellaNav StablePoint; Opal HDx Ablation

  3. P150005/S090 received

    Application receipt date recorded by FDA.

  4. P150005/S091 · Related supplement

    RHYTHMIA HDx Ablation Connection Box (for INTELLAGEN) (M004RA65010); Rhythmia HDx Ablation Connection Box (Maestro)

  5. P150005/S090 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P150005. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150005

Explore the linked device profile

Other records with product code OAD

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA
Irvine Biomedical,Inc.(Ibi)PMA supplementSep 3, 2026FDA
Biosense Webster, Inc.PMA supplementSep 2, 2026FDA
Ampere GeneratorP040042/S059
Irvine Biomedical,Inc.(Ibi)PMA supplementAug 7, 2026FDA
Ampere GeneratorP060019/S059
Irvine Biomedical, Inc.PMA supplementAug 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records